ClinicalTrials.gg
CompletedNCT03994549Updated Dec 2, 2020

A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

An Early Phase 1 interventional study of Dual GLP-1/GLP-2 Receptor agonists in Healthy, sponsored by Zealand Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-02.

Sponsored by Zealand Pharma · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, single ascending dose trial in healthy subjects, randomized to ZP7570 or placebo within each cohort.

Read the detailed description

Sixty-four subjects are planned to be studied in eight cohorts in this first-in human trial. Eight subjects will be allocated to the to eight dose levels. The entire observation period comprise 28 days starting with a 96 hours in-house stay, where discharge is planned for Day 5, followed by five outpatient visits and an End of Trial Visit at Day 28. A blinded evaluation of each cohort will be performed by a Trial Safety Group to determine whether the trial will progress to the next dose level based on the stopping rules specified in protocol.

02

Conditions studied

  • Healthy

Keywords

  • Dual GLP-1R/GLP-2 Receptor agonist
03

In context

Lead sponsor

Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subject aged between 18 and 55 years, both inclusive.
  • (BMI) between 18.5 and 28.0 kg/m\^2, both inclusive
  • Body weight of at least 60 kg.
  • Heart rate after 5 minutes rest in supine position inside the range of 50-90 beats/min at screening

Exclusion criteria

Exclusion Criteria:

  • Any history of a disorder which in the investigator's opinion might jeopardize subjects safety, evaluation of results or compliance with the protocol.
  • History of gallbladder disease or cholecystectomy.
  • History of major depressive disorder or a Patient Health Questionnaire (PHQ-9) > 9 completed at screening, or a history of other severe psychiatric disorders (e.g. schizophrenia or bipolar disorder).
  • Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to screening.
  • abnormal standard 12-lead after 5 min resting in supine position at screening, including a > 450 ms (males) or QTcF > 470 ms (females), PR ≥ 220 ms and QRS ≥ 110 ms as evaluated by the investigator.
  • History of severe to medicines or foods or history of severe medicinal/food induced anaphylactic reaction or to the use of Indocyanine Green (e.g. hypersensitivity to iodine).
  • Any clinically significant abnormal hematology, biochemistry, or urinalysis screening tests, as judged by the investigator.
  • TSH values outside of normal reference ranges of safety laboratory
  • Estimated (eGFR) \< 90 ml/min/1.73 m2, as defined by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
  • Known or suspected hypersensitivity to IMP(s) or related products.
  • Systolic blood pressure \< 90 mmHg or >139 mmHg and/or diastolic blood pressure \< 50 mmHg or > 89 mmHg (one repeat test will be acceptable in case of suspected white-coat hypertension).
  • Symptoms of arterial hypotension
  • Women of who are not using a highly effective method
  • Men with non-pregnant partner(s) of childbearing potential not willing to use male contraception (condom) in addition to a highly effective contraceptive method until 28 days after dosing
  • Men with pregnant partner not willing to use male contraception (condom) until 28 days after dosing, in order to avoid exposure of the embryo/fetus to seminal fluid
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    ZP7570

    Single subcutaneous injection

    Drug: Dual GLP-1/GLP-2 Receptor agonists

  • Placebo comparator
    Placebo

    Single subcutaneous injection

    Drug: Dual GLP-1/GLP-2 Receptor agonists

Interventions

  • DrugDual GLP-1/GLP-2 Receptor agonists

    Drug page: Dapiglutide

    Eight ascending doses of ZP7570

    Also known as: ZP7570

06

What researchers measure

Primary outcomes

  1. Safety - Incidence of adverse events (AEs)

    The incidence, type and severity of adverse events (AEs)

    Time frame: From time zero to 28 days after dosing

Secondary outcomes

  1. Pharmacokinetics - Area under the plasma concentration-time curve trough

    AUCτ, Area under the plasma concentration-time curve (AUC) from zero up to trough concentration.

    Time frame: From time zero up to day 28

  2. Pharmacokinetics - Area under the plasma concentration-time curve infinity

    AUCinf, Area under the plasma concentration-time curve (AUC) from zero up to last concentration.

    Time frame: From time zero up to day 28

  3. Pharmacokinetics - Area under the plasma concentration-time curve last

    AUClast, Area under the plasma concentration-time curve (AUC) from zero up to last concentration

    Time frame: From time zero up to day 28

  4. Pharmacokinetics - Maximum plasma concentration

    Measured maximum plasma drug concentration after dosing, Cmax

    Time frame: From time zero to 28 days after dosing

  5. Pharmacokinetics - Time to maximum plasma concentration (Tmax)

    Sampling time until reaching Cmax, Tmax

    Time frame: From time zero to 28 days after dosing

  6. Pharmacokinetics - Half-life , t½

    Half-life of ZP7570, t½

    Time frame: From time zero to 28 days after dosing

  7. Pharmacokinetics - Volume of distribution

    Apparent volume of distribution of ZP7570, Vz/f

    Time frame: From time zero to 28 days after dosing

  8. Pharmacokinetics - Mean residence time

    Mean residence time, MRT

    Time frame: From time zero to 28 days after dosing

  9. Pharmacokinetics - Body clearance

    Total body clearance, CL/f

    Time frame: From time zero to 28 days after dosing

  10. Pharmacokinetics - Elimination rate constant

    Elimination rate constant, λz

    Time frame: From time zero to 28 days after dosing

  11. Pharmacodynamics - Plasma glucose levels

    Plasma glucose levels included with the acetaminophen at specific timepoints relative to a Mixed Test Meal

    Time frame: Time Frame: 0-240 minutes

  12. Pharmacodynamics - Insulin concentrations

    Insulin concentrations included with the acetaminophen at specific timepoints relative to a Mixed Test Meal

    Time frame: Time Frame: 0-240 minutes

  13. Pharmacodynamics - Plasma acetaminophen concentration-time curves

    Plasma acetaminophen concentration-time curves following ingestion of acetaminophen

    Time frame: Time Frame: 0-240 minutes

  14. Pharmacodynamics - Maximum acetaminophen concentration

    Change from baseline acetaminophen to maximum acetaminophen

    Time frame: Time Frame: 0-240 minutes

  15. Pharmacodynamics - Time maximum acetaminophen concentration

    Time to maximum change in acetaminophen measure from baseline, Tmax

    Time frame: Time Frame: 0-240 minutes

  16. Safety - Safety lab, haematology

    Changes in haematology parameters: Haematocrit, Haemoglobin, Erythrocytes, MCV, MCH, MCHC, platelets, Leucocytes, Neutrophile granulocytes (total count and relative), Lymphocytes (total count and relative), Monocytes (total count and relative), Eosinophile granulocytes (total count and relative), Basophile granulocytes (total count and relative)

    Time frame: From time zero to 28 days after dosing

  17. Safety - Safety lab, clinical chemistry

    Changes in clinical chemistry parameters: Sodium, Potassium, Calcium, Creatinine, Urea, AST, ALT, gamma-GT, Uric acid, Total protein, Albumin, Total bilirubin, Creatine kinase, Alkaline phosphatase, LDH, Total cholesterol, LDL, HDL, Amylase, Triglycerides, Lipase

    Time frame: From time zero to 28 days after dosing

  18. Safety - Safety lab, urinalysis

    Changes in urinalysis: Protein, Glucose Erythrocytes, Leucocytes, pH, ketones

    Time frame: From time zero to 28 days after dosing

  19. Safety - Vital signs, blood pressure

    Changes in vital signs, blood pressure (in mmHG)

    Time frame: From time zero to 28 days after dosing

  20. Safety - Vital signs, pulse

    Changes in pulse (beats per minute)

    Time frame: From time zero to 28 days after dosing

  21. Safety - Physical examination

    Changes in physical examination of body sections (head, chest and heart, abdomen, skin and mucosae, musculoskeletal system, nervous system, lymph node)

    Time frame: From time zero to 28 days after dosing

  22. Safety - ECG

    Occurrence of ECG findings, Changes in ECG parameters (in ms). ECG components: Heart rate, PR, QRS, QT and QTcF.

    Time frame: From time zero to 28 days after dosing

  23. Safety - Occurrence of Injection site reactions

    Occurrence of injection site reactions

    Time frame: From time zero to 28 days after dosing

  24. Safety - Immunogenicity: Occurrence of anti-drug antibodies

    Occurrence of anti-drug antibodies

    Time frame: From time zero to 28 days after dosing

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, North Rhine-Westphalia 41460, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Nov 2020, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
Jun 21, 2019
StartActual
Jun 14, 2019
Primary completionActual
Nov 2, 2020
CompletionActual
Nov 2, 2020
Last update
Dec 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03994549
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Jun 21, 2019
Start date
Jun 14, 2019
Primary completion
Nov 2, 2020
Completion
Nov 2, 2020
Last update
Dec 2, 2020

Study contacts

Ulrike Hövelmann, MD
principal investigator · Profil Neuss, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapiglutide

Start the discussion